Table 1 Results of univariate and multivariate models assessing HR of exposures on lymphoma development in SLE patients
From: Lymphoma risk in systemic lupus: effects of treatment versus disease activity
Variable | Univariate HR (95% CI) | Partially adjusted model (95% CI) | Multivarate HR (95% CI) |
|---|---|---|---|
Cyclophosphamide (CY) ever | 1.73 (0.90 to 3.33) | 1.99 (1.00 to 3.96) | 1.95 (0.61 to 6.22) |
Cumulative CY >6 g | 1.51 (0.63 to 3.62) | - | 0.79 (0.18 to 3.54) |
Azathioprine (AZA) ever | 0.82 (0.45 to 1.52) | - | 1.28 (0.53 to 3.07) |
Cumulative AZA >36.5 g | 0.49 (0.19 to 1.25) | - | 0.46 (0.14 to 1.54) |
Methotrexate ever used | 0.99 (0.45 to 2.16) | - | 0.79 (0.30 to 2.05) |
Mycophenolate ever used | 1.38 (0.58 to 3.29) | - | 1.74 (0.70 to 4.34) |
Antimalarials ever used | 1.47 (0.80 to 2.69) | - | 1.39 (0.69 to 2.78) |
Glucocorticosteroids (GC) ever | 1.39 (0.75 to 2.56) | - | 1.03 (0.40 to 2.64) |
Cumulative GCa >3.5 g | 1.27 (0.75 to 2.17) | - | 1.59 (0.69 to 3.67) |
Disease activity (second tertile)b | 1.00 (0.55 to 1.82) | - | 1.10(0.56 to 2.14) |
Disease activity (third tertile) | 0.43 (0.22 to 0.84) | 0.49 (0.27 to 0.90) | 0.52 (0.24 to 1.12) |
Outside North America | 1.04 (0.53 to 2.05) | - | 1.06 (0.45 to 2.50) |
Male | 2.47 (1.24 to 4.92) | - | 2.21 (1.05 to 4.66) |
Age | 1.05 (1.03 to 1.07) | 1.04 (1.03 to 1.06) | 1.05 (1.03 to 1.07) |
White race/ethnicity | 0.97 (0.55 to 1.71) | - | 0.86 (0.46 to 1.59) |
Calendar year | 1.01 (0.98 to 1.05) | - | 0.98 (0.94 to 1.02) |
Sjögren's syndrome | 1.29 (0.66 to 2.54) | - | 1.21 (0.53 to 2.78) |